Bladder preservation with targeted drugs and radiation for HER2-positive bladder cancer
Treatments studied
This trial tests a combination of two drugs (trastuzumab rezetecan and adebrelimab) plus radiation to the bladder, aiming to preserve the bladder instead of removing it. It's for people with muscle-invasive bladder cancer that shows a specific marker called HER2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have muscle-invasive bladder cancer (stage cT2-T4a, N0, M0) that has not spread to other organs.
- Your tumor tests positive for HER2 (at least 1+ by IHC).
- You are fit enough to have surgery (maximal TURBT) and radiation therapy.
- You have not had prior chemotherapy, immunotherapy, or radiation for this bladder cancer.
- Your heart, liver, and kidney function are within acceptable ranges, and you have no serious lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two drugs before and after surgery can help people with HER2-positive bladder cancer that has grown into the bladder muscle. The goal is to see if this approach can shrink or control the cancer before the bladder is removed.
This trial tests two drugs, trastuzumab rezetecan and adebrelimab, given before surgery for a type of bladder cancer that has grown into the muscle. The goal is to see if this combination can shrink the tumor and improve outcomes for patients whose cancer cells have a certain protein called HER2.
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
This trial tests a new treatment approach using MRI to guide bladder preservation for patients with muscle-invasive bladder cancer. The goal is to treat the cancer with chemotherapy and radiation instead of removing the bladder, potentially allowing you to keep your bladder while fighting the cancer.
This trial tests a combination of probiotics, targeted therapy (RC48-ADC), and immunotherapy (Toripalimab) to treat muscle-invasive bladder cancer while preserving the bladder. The goal is to see if this combination can shrink or eliminate the cancer without needing bladder removal.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
Hear when a new Muscle-Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.